Rabeprazole Sodium 20mg & Levosulpiride 75mg Capsules (Sustained Release Pellets)
Formulation Overview: Advanced prokinetic-PPI capsule pairing enteric-coated rabeprazole with sustained-release levosulpiride 75 mg to enhance lower esophageal sphincter tone and accelerate antroduodenal coordination. Formulated with Rabeprazole Sodium IP 20 mg (EC) + Levosulpiride 75 mg (SR Pellets) (20 mg + 75 mg (SR)) in Sustained-Release Pellet Capsules dosage form under Gastroenterology & PPIs, manufactured to IP / BP / USP Compendial standards and supplied in 10 x 10 Alu-Alu Blister Pack with complete eCTD/ACTD regulatory dossiers, Zone IVb stability, and batch CoA for African NRAs (NAFDAC, PPB, SAHPRA, TMDA, FDA Ghana) and global tenders.
| Item Code (SKU) | AKP-015 |
| Therapeutic Sector | Gastroenterology & PPIs |
| Dosage Form | Sustained-Release Pellet Capsules |
| Active Ingredient | Rabeprazole Sodium IP 20 mg (EC) + Levosulpiride 75 mg (SR Pellets) |
| Strength / Purity | 20 mg + 75 mg (SR) |
| Clinical Indication | Refractory GERD, diabetic gastroparesis, and irritable bowel-associated upper dyspepsia |
| Specification Standard | IP / BP / USP Compendial |
| Packaging Format | 10 x 10 Alu-Alu Blister Pack |
| Shelf Life | 24–36 Months |
| Storage Conditions | Store below 25°C, protect from moisture & direct sunlight |
| Minimum Order Quantity | 1000 Packs |
| Regulatory / Analytical Docs | Full eCTD / ACTD Modules 1–5 + Zone IVb Stability Available |
| African & Global NRA Readiness | NAFDAC (Nigeria), PPB (Kenya), SAHPRA (SA), TMDA (Tanzania), FDA Ghana, AIRP, ARP, EFDA |
| Stock Availability | In Stock · Immediate Commercial Dispatch |
| Supply Status | Commercial Export Ready |